BOSTON--(BUSINESS WIRE)-- Pear Therapeutics., the leader in prescription digital therapeutics (PDTs), is building a robust intellectual property (“IP”) portfolio covering prescription PDTs. PDTs are software that treat serious disease based on a label from the U.S. Food and Drug Administration, and they are used under the supervision of a prescribing physician. Pear is committed to protecting patient data and complying with applicable laws and regulations concerning access to and use of patient data. To that end, Pear today announced the recent granting by the United States Patent and Trademark Office of US Patent No. 10,986,071, entitled “Systems and Methods for Ensuring Data Security in the Treatment of Diseases and Disorders Using Digital Therapeutics.”

“Our patents and other IP reflect our commitment to innovation, and we believe our IP strengthens our leading position in the PDT category,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. “We are always working to add to our IP portfolio to generate business value for our shareholders as we innovate for our patients.”

Pear has a foundational IP estate including more than 20 owned and licensed patients covering more than 600 claims for a variety of different aspects related to PDTs. In addition to its own utility and design patents, Pear is the exclusive licensee to a portfolio of utility patents that encompasses more than 550 granted claims directed primarily to drug/software combinations and that may potentially cover aspects of current or future PDTs. Like other software, PDTs are protected by copyright, trademark, and trade secrets.

Pear Therapeutics

Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst®, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005220/en/